TP53 and acute myeloid leukemia: SIRT1 expression correlated with increased resistance to targeted therapy of FLT3-mutated AML cells [60], and SIRT1 pharmacological targeting inhibited cell growth and sensitized AML cells to treatment with tyrosine kinase inhibitors and chemotherapy via restoration of p53 activity [1].